TABLE 1.
Demographic and clinical disease characteristics of patients with resected nonpancreatic periampullary adenocarcinoma by receipt of neoadjuvant therapy (NAT) or upfront resection (UR) in the NCDB (2006–2016)
| Extrahepatic cholangiocarcinoma |
Ampullary adenocarcinoma |
Duodenal adenocarcinoma |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| UR (N = 2357) | NAT (N = 157) | p | UR (N = 3668) | NAT (N = 94) | p | UR (N = 1765) | NAT (N = 123) | p | |
|
| |||||||||
| Age, years | 68 (60–75) | 64 (53–72) | <0.001 | 68 (59–76) | 67 (59–72) | 0.167 | 67 (58–76) | 60 (50–68) | <0.001 |
| Female gender | 852 (36.1%) | 55 (35.0%) | 0.798 | 1565 (42.7%) | 35 (37.2%) | 0.342 | 791 (44.8%) | 58 (47.2%) | 0.640 |
| Race | |||||||||
| White | 1994 (84.6%) | 138 (87.9%) | 0.456 | 3091 (84.3%) | 82 (87.2%) | 0.271 | 1397 (79.2%) | 92 (74.8%) | 0.517 |
| Black | 183 (7.8%) | 11 (7.0%) | 254 (6.9%) | 8 (8.5%) | 282 (16.0%) | 24 (19.5%) | |||
| Other | 180 (7.6%) | 8 (5.1%) | 323 (8.8%) | 4 (4.3%) | 86 (4.9%) | 7 (5.7%) | |||
| Insured | 2272 (97.9%) | 151 (98.7%) | 0.767 | 3507 (96.6%) | 89 (95.7%) | 0.559 | 1685 (97.0%) | 115 (99.1%) | 0.253 |
| Comorbidity score* | |||||||||
| 0 | 1645 (69.8%) | 122 (77.7%) | 0.099 | 2583 (70.4%) | 65 (69.1%) | 0.455 | 1222 (69.2%) | 90 (73.2%) | 0.330 |
| 1 | 537 (22.8%) | 25 (15.9%) | 832 (22.7%) | 25 (26.6%) | 390 (22.1%) | 27 (22.0%) | |||
| ≥ 2 | 175 (7.4%) | 10 (6.4%) | 253 (6.9%) | 4 (4.3%) | 153 (8.7%) | 6 (4.9%) | |||
| Hospital location | |||||||||
| Midwest | 583 (25.2%) | 52 (36.4%) | 0.001 | 894 (24.8%) | 28 (31.1%) | 0.175 | 438 (25.6%) | 33 (28.2%) | 0.693 |
| South | 846 (36.5%) | 39 (27.3%) | 1345 (37.2%) | 37 (41.1%) | 654 (38.2%) | 47 (40.2%) | |||
| Northeast | 546 (23.6%) | 22 (15.4%) | 741 (20.5%) | 16 (17.8%) | 387 (22.6%) | 25 (21.4%) | |||
| West | 342 (14.8%) | 30 (21.0%) | 632 (17.5%) | 9 (10.0%) | 235 (13.7%) | 12 (10.3%) | |||
| Hospital type | |||||||||
| Academic | 1479 (63.8%) | 98 (68.5%) | 0.247 | 2085 (57.7%) | 61 (67.8%) | 0.127 | 962 (56.1%) | 72 (61.5%) | 0.396 |
| Comprehensive community | 786 (33.9%) | 40 (28.0%) | 1415 (39.2%) | 28 (31.1%) | 693 (40.4%) | 40 (34.2%) | |||
| Community | 52 (2.2%) | 5 (3.5%) | 112 (3.1%) | 1 (1.1%) | 59 (3.4%) | 5 (4.3%) | |||
| Year of diagnosis** | |||||||||
| 2006 | 93 (93.9%) | 6 (6.1%) | <0.001 | 153 (98.7%) | 2 (1.3%) | 0.013 | 88 (93.6%) | 6 (6.4%) | 0.008 |
| 2007 | 113 (93.4%) | 8 (6.6%) | 167 (98.2%) | 3 (1.8%) | 95 (97.9%) | 2 (2.1%) | |||
| 2008 | 199 (97.5%) | 5 (2.5%) | 293 (98.3%) | 5 (1.7%) | 152 (93.3%) | 11 (6.7%) | |||
| 2009 | 231 (97.5%) | 6 (2.5%) | 352 (98.6%) | 5 (1.4%) | 170 (96.0%) | 7 (4.0%) | |||
| 2010 | 251 (93.0%) | 19 (7.0%) | 377 (97.7%) | 9 (2.3%) | 183 (94.8%) | 10 (5.2%) | |||
| 2011 | 248 (96.5%) | 9 (3.5%) | 342 (97.4%) | 9 (2.6%) | 177 (94.1%) | 11 (5.9%) | |||
| 2012 | 239 (92.3%) | 20 (7.7%) | 373 (96.9%) | 12 (3.1%) | 184 (93.4%) | 13 (6.6%) | |||
| 2013 | 258 (94.5%) | 15 (5.5%) | 454 (97.2%) | 13 (2.8%) | 182 (92.9%) | 14 (7.1%) | |||
| 2014 | 268 (93.7%) | 18 (6.3%) | 434 (98.0%) | 9 (2.0%) | 205 (94.0%) | 13 (6.0%) | |||
| 2015 | 254 (90.7%) | 26 (9.3%) | 384 (97.0%) | 12 (3.0%) | 173 (90.6%) | 18 (9.4%) | |||
| 2016 | 203 (89.0%) | 25 (11.0%) | 339 (95.8%) | 15 (4.2%) | 156 (89.7%) | 18 (10.3%) | |||
| Clinical stage | |||||||||
| I | 1101 (46.7%) | 64 (40.8%) | 0.148 | 2185 (59.6%) | 30 (31.9%) | 0.001 | 580 (32.9%) | 10 (8.1%) | <0.001 |
| II | 1256 (53.3%) | 93 (59.2%) | 1483 (40.4%) | 64 (68.1%) | 646 (36.6%) | 52 (42.3%) | |||
| III | 539 (30.5%) | 61 (49.6%) | |||||||
| Neoadjuvant RT | 0 | 76 (48.4%) | – | 0 | 35 (37.2%) | – | 0 | 59 (48.8%) | |
Data are presented as n (%) or median (IQR); data for all categorical variables are presented as column percentages, except for the variable
*
Charlson–Deyo comorbidity score
**
Year of diagnosis where data are presented as row percentages to reflect temporal trends per year; percentages may not add up to 100% owing to missing data NCDB National Cancer Data Base, UR upfront resection, NAT neoadjuvant therapy, IQR interquartile range, MIS minimally invasive resection